Elina Makino is a prominent inventor based in Winchester, MA (US), known for her significant contributions to the field of metabolic disease treatments. With a total of five patents to her name, she has made remarkable strides in developing innovative therapies aimed at addressing complex health conditions.

Latest Patents

Among her latest patents, Elina has developed glucosylceramide synthase inhibitors. This invention relates to inhibitors of glucosylceramide synthase (GCS), which are useful for treating metabolic diseases, including lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease, and cancer. Another notable patent involves UDP glycosyltransferase inhibitors and methods of use. This patent describes a compound and its pharmaceutically acceptable salts, along with compositions and methods for treating various diseases, particularly Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).

Career Highlights

Elina Makino is currently associated with Genzyme Corporation, where she continues to advance her research and development efforts. Her work has been instrumental in creating therapies that improve the quality of life for patients suffering from serious metabolic disorders.

Collaborations

Elina collaborates with talented professionals in her field, including Bradford Hirth and Elyse Bourque. These partnerships enhance her research capabilities and contribute to the innovative solutions she develops.

Conclusion

Elina Makino's work exemplifies the impact of innovation in the medical field, particularly in the treatment of metabolic diseases. Her patents and ongoing research are paving the way for new therapeutic options that can significantly benefit patients.

This text is generated by artificial intelligence and may not be accurate.